The Same Molecule, Two Products
Ozempic and Wegovy are both brand names for semaglutide — a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. At the molecular level, they are identical: the same amino acid sequence, the same fatty acid chain that extends the half-life to approximately 7 days, and the same mechanism of action — binding GLP-1 receptors in the pancreas, brain, stomach, and gut to improve insulin secretion, suppress appetite, and slow gastric emptying.
The difference lies entirely in their approved indications, their maximum approved doses, the clinical trials used to support those approvals, and consequently in how insurance and formulary systems treat them. Understanding this distinction is practically important for anyone considering semaglutide therapy — the product your provider prescribes has significant implications for cost, access, and dosing ceiling.
FDA Approval Differences
Ozempic received FDA approval in December 2017 for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults. A secondary approval for cardiovascular risk reduction followed in 2020 (based on the SUSTAIN-6 trial demonstrating reduced major adverse cardiovascular events in patients with T2D and established cardiovascular disease). Ozempic is not FDA-approved for weight loss or obesity treatment in non-diabetic patients.
Wegovy received FDA approval in June 2021 specifically for chronic weight management in adults with a BMI of ≥30 kg/m² (obesity), or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). In March 2024, Wegovy received an additional approval for cardiovascular risk reduction in adults with obesity and established cardiovascular disease — making it the first weight loss medication approved to reduce heart attack and stroke risk.
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approval year | 2017 | 2021 |
| Approved indication | Type 2 diabetes; CV risk reduction (T2D) | Chronic weight management; CV risk reduction (obesity) |
| Maximum dose | 2 mg/week (with T2D CV indication) | 2.4 mg/week |
| Typical maintenance dose | 0.5–1.0 mg/week | 2.4 mg/week |
| Injection frequency | Once weekly | Once weekly |
| Pen device | Ozempic pen (0.25, 0.5, 1.0, 2.0 mg doses) | Wegovy pen (separate device, fixed doses) |
Dosing: Why Wegovy Goes Higher
The most clinically significant difference between Ozempic and Wegovy is the maximum dose — 1–2 mg/week for Ozempic vs. 2.4 mg/week for Wegovy. This is not arbitrary. The STEP clinical trials that led to Wegovy's approval specifically tested 2.4 mg/week and found that this dose produced meaningfully greater weight loss than lower doses, with a dose-response relationship that continued up to the maximum dose studied.
For context: in the SUSTAIN-6 trial (supporting Ozempic's T2D approval), patients received up to 1 mg/week of semaglutide and lost approximately 4–5% of body weight as a secondary finding. In the STEP-1 trial (supporting Wegovy's obesity approval), patients received 2.4 mg/week and lost an average of 14.9% of body weight — nearly three times as much. The higher dose significantly improves appetite suppression by achieving a more robust effect on hypothalamic GLP-1 receptors.
This means that a patient who uses Ozempic for weight loss — a common off-label practice — is pharmacologically capped at a lower dose and will typically achieve less weight loss than a patient using Wegovy at its full approved dose.
The SUSTAIN vs. STEP Trial Comparison
The clinical trial programs behind these two products tell different stories about what semaglutide was designed to accomplish:
The SUSTAIN program (SUSTAIN 1–10) was designed to demonstrate Ozempic's efficacy and safety in people with type 2 diabetes, comparing it to placebo, other diabetes medications (sitagliptin, glimepiride, insulin), and other GLP-1 agonists. The primary endpoints were glycemic control (HbA1c reduction) and cardiovascular outcomes. Weight loss was a secondary and welcomed finding.
The STEP program (STEP 1–5) was designed to demonstrate Wegovy's efficacy and safety as a weight management medication in people with obesity or overweight — not specifically people with diabetes. The primary endpoint was weight loss. The STEP-1 trial (non-diabetic adults) showed 14.9% average weight loss at 68 weeks; STEP-2 (adults with T2D) showed 9.6%; STEP-3 (with intensive behavioral intervention) showed 16%; STEP-5 (two-year data) showed sustained loss of 15.2%. The SELECT trial, which led to Wegovy's 2024 cardiovascular approval, showed 20% reduction in major adverse cardiovascular events in obese patients with established CVD.
Insurance: Why Coverage Differs Dramatically
The insurance coverage landscape for Ozempic vs. Wegovy reflects the FDA indication difference and the historical reluctance of insurers to cover medications for obesity:
Ozempic is typically covered by commercial insurance plans for patients with type 2 diabetes, as it has a clear FDA approval for that indication and strong clinical evidence for glycemic control and cardiovascular benefit. Most Medicare Part D plans also cover Ozempic for T2D.
Wegovy coverage is far more variable. Although it has a clear FDA approval for obesity — a recognized chronic disease — many commercial insurers and most traditional Medicare plans do not cover it, citing the medication's cost and the historical exclusion of weight loss drugs from formularies. The Treat and Reduce Obesity Act, passed to allow Medicare Part D coverage of obesity medications, was implemented gradually, and coverage expansion is ongoing. Some employers and self-insured plans specifically exclude GLP-1 medications for weight loss, while others have added coverage due to employee demand.
This insurance difference is a primary driver of why many providers prescribe Ozempic off-label for weight loss — it may be covered when Wegovy is not. The trade-off is a lower maximum dose ceiling and an off-label use that some insurers may scrutinize.
Can You Use Ozempic for Weight Loss?
Prescribing Ozempic for weight loss in a non-diabetic patient is off-label — meaning the FDA has not approved it for this specific use, but providers are legally permitted to prescribe any approved medication for off-label uses at their clinical discretion. Off-label prescribing is common in medicine (approximately 20% of all prescriptions in the US are off-label).
Ozempic does produce meaningful weight loss at 0.5–1.0 mg/week — typically 5–10% of body weight with concurrent lifestyle modification. For patients who cannot access Wegovy due to insurance barriers, Ozempic offers a clinically meaningful alternative with the understanding that the weight loss will likely be less than with Wegovy 2.4 mg/week.
Availability and Shortage History
Both Ozempic and Wegovy experienced significant supply shortages starting in 2022 as demand dramatically outpaced manufacturing capacity. Wegovy shortages were particularly severe at launch and contributed to many providers pivoting to Ozempic as an available alternative. Novo Nordisk has substantially increased production capacity since 2022, and availability has improved considerably in the US market, though regional and pharmacy-level shortages still occur intermittently.